Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 2,900 shares, a drop of 27.5% from the August 31st total of 4,000 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is currently 0.5 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Advaxis in a report on Monday, August 22nd. They set a "sell" rating for the company.
Get Advaxis alerts:Advaxis Stock Performance
Advaxis stock traded down $0.04 during mid-day trading on Friday, hitting $2.16. 4,192 shares of the company's stock traded hands, compared to its average volume of 6,242. The company has a 50 day moving average of $3.20. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $44.80. The stock has a market capitalization of $3.92 million, a PE ratio of -21.60 and a beta of 2.07.
Advaxis Company Profile
(Get Rating)
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Read More
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Let Paychex Stock Work Hard For You
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
